Conivaptan is an antidiuretic hormone inhibitor used to raise serum sodium levels. It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).
- Mechanism
- Curator reviewed
Conivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water.
- Primary indication
- For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.Curator reviewed · 2 structured indications
- Formula / weight
- C32H26N4O2 · 498.5744 g/mol (avg)
- First approval
- United States, 2005
- Code names
- YM-087
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
IKENVDNFQMCRTR-UHFFFAOYSA-NSMILESCC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1Targets
Transporters
What you can answer from here — as of September 23, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Conivaptan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account